Alcon Terminates Merger Agreement with STAAR, Focuses on New Product Launches
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1d ago
0mins
Source: Businesswire
- Merger Agreement Termination: Alcon has terminated its merger agreement with STAAR Surgical, reflecting the company's disciplined approach to price and risk management, ensuring stability in its strategic direction.
- Continued Product Focus: Despite the failed merger, Alcon remains focused on its new wavelight®plus offering, aimed at enhancing outcomes for LASIK surgery globally, thereby reinforcing its market leadership.
- Product Launch Plans: Alcon plans to globally launch over 10 major products this year across its surgical and vision care franchises, which will significantly improve treatment outcomes for eye care disorders and help patients enhance their vision worldwide.
- Industry Impact: As the global leader in eye care, Alcon serves over 260 million people annually, and its innovative products and partnerships with eye care professionals will continue to drive growth in the eye care market.
Analyst Views on ALC
Wall Street analysts forecast ALC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALC is 93.78 USD with a low forecast of 80.00 USD and a high forecast of 112.74 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
9 Buy
3 Hold
0 Sell
Strong Buy
Current: 81.810
Low
80.00
Averages
93.78
High
112.74
Current: 81.810
Low
80.00
Averages
93.78
High
112.74
About ALC
Alcon AG is a Switzerland-based eye care company. The Company research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The Company operates in 60 countries and serves consumers and patients in over 140 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
